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Abstract: Paternally expressed gene 10 (PEG10) is a human retrotransposon-derived imprinted 
gene. The mRNA of PEG10 encodes two protein isoforms: the Gag-like protein (RF1PEG10) is coded 
by reading frame 1, while the Gag-Pol-like polyprotein (RF1/RF2PEG10) is coded by reading frames 1 
and 2. The proteins are translated by a typical retroviral frameshift mechanism. The protease (PR) 
domain of RF2PEG10 contains an -Asp-Ser-Gly- sequence, which corresponds to the consensus -Asp-
Ser/Thr-Gly- active-site motif of retroviral aspartic proteases. The function of the aspartic protease 
domain of RF2PEG10 remains unclear. To elucidate the function of PEG10 protease (PRPEG10), we 
designed a frameshift mutant (fsRF1/RF2PEG10) for comparison with the RF1/RF2PEG10 form. To study 
the effects of PRPEG10 on cellular proliferation and viability, mammalian HEK293T and HaCaT cells 
were transfected with plasmids coding for either RF1/RF2PEG10, the frameshift mutant 
(fsRF1/RF2PEG10), or a PR active-site (D370A) mutant fsRF1/RF2PEG10. Our results indicate that 
fsRF1/RF2PEG10 overexpression results in increased cellular proliferation. Remarkably, transfection 
with fsRF1/RF2PEG10 had a detrimental effect on cell viability. We hypothesize that PRPEG10 plays an 
important role in the function of this retroviral remnant, mediating the proliferation of cells and 
possibly implicating it in the inhibition of apoptosis. 
Keywords: PEG10; paternally expressed gene 10; cell viability; cell proliferation; cis protease 
activity; ubiquitination; homology modeling; retroviral-like protease; protease; retrotransposon 
 
1. Introduction 
Paternally expressed gene 10 (PEG10) is an imprinted gene located on the human chromosome 
7q21 and is known to have evolved from a retroviral element, although it has lost the ability to 
replicate independently [1]. This domesticated retroviral remnant has been shown to be essential for 
embryonic development in mice; previous studies demonstrated that mutations in the coding 
sequence of the gene are lethal in the embryonic stage because of defects in placental development 
[2]. Additionally, upregulated PEG10 expression has been observed in malignancies such as 
hepatocellular carcinoma [3–6], embryonic kidney Wilms’ tumor [7], lung cancer [8], breast cancer 
[9], and pancreatic cancer [10,11]. Although endogenous expression of PEG10 had previously been 
detected using antibodies in the human liver cancer cell line HepG2 and human embryonic kidney 
cells (HEK), more sensitive methods revealed that other cell lines, such as breast tumor and large-cell 
lung carcinoma cells, also express PEG10 [12]. The mRNA of PEG10 encodes at least two protein 
isoforms: the major PEG10 protein product reading frame 1 (RF1PEG10) and reading frames 1 and 2 
(RF1/RF2PEG10), which are translated by a typical retroviral-1 ribosomal frameshift mechanism [13–
16]. RF1PEG10 encodes a Gag-like protein, and RF1/RF2PEG10 encodes a Gag-Pol-like polyprotein that is 
characteristic to retroviruses and retroelements. Additionally, RF1PEG10 has a conserved major 
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homology domain and a CCHC-type Zn-finger motif in its structure (Cys-X2-Cys-X4-His-X4-Cys). 
Shortly following the -1 ribosomal frameshift site, RF2PEG10 contains a consensus -Asp-Ser-Gly- 
sequence motif (Figure 1) that is characteristic of retroviral aspartic proteases; this domain is followed 
by a truncated reverse transcriptase domain [17]. 
While the anti-apoptotic role of RF1PEG10 was previously investigated [18–20], the role of RF2PEG10 
has not yet been elucidated. The predicted post-translational modifications of RF2PEG10, such as 
phosphorylation and dephosphorylation, may be essential for the regulation of PEG10 function [15]. 
Considering its importance, the −1 translational frameshift mechanism of RF1/RF2PEG10 has been 
thoroughly investigated. Lux et al. [12] cloned the entire RF1/RF2PEG10 sequence into an eukaryotic 
expression vector. RF1/RF2PEG10 was then expressed in transfected COS-1 cells, and the cell lysate was 
analyzed by Western blot. Three protein bands were identified that corresponded to the full length 
of RF1/RF2PEG10, as well as RF1PEG10 and a shorter N-terminal fragment (PEG10-cleaved N-terminus 
fragment), which was considered to be most likely a cleavage product of an aspartic protease [12]. 
Analysis of the proteolytic activity of PEG10 protease (PRPEG10) was previously attempted using an 
active-site mutant, where the conserved aspartate was mutated to alanine, thereby impairing its 
catalytic activity [15]. Even though the authors verified the proteolytic activity of PRPEG10, it is unclear 
whether this proteolytic activity is required for the function of PEG10, or whether PRPEG10 has simply 
persisted as an evolutionary remnant. We assumed that the PEG10 is involved in the regulation of 
cell proliferation and has anti-apoptotic effects due to the protease (PR) activity of RF2PEG10. Based on 
this hypothesis, and if proven correct, PRPEG10 may be effectively targeted for chemotherapeutic 
purposes. 
In this study, we focused on the aspartic protease domain of RF1/RF2PEG10, a part of RF2PEG10. 
Although PRPEG10 is believed to mediate polyprotein processing in a similar manner to other retroviral 
PRs [15], neither the biochemical characteristics of this protease nor its functional importance have 
been established to date. Therefore, we aimed to investigate the activity of PRPEG10 and study its 
involvement in the function of PEG10. The activity of PRPEG10 was proven by investigating 
autoproteolysis of wild-type and active site mutant RF1/RF2PEG10 proteins in the lysates of transfected 
HEK293T cells. Furthermore, functional studies were performed in order to investigate whether 
overexpression of frameshift mutant fsRF1/RF2PEG10 affects the proliferation and viability of 
transfected human embryonic kidney 293T (HEK293T) and human keratinocyte HaCaT cells. 
2. Results 
2.1. In Silico Analyses 
Data about PRPEG10 are limited, therefore in silico methods were applied to investigate its 
structural characteristics. Results of secondary structure prediction implied that the conserved active-
site motif and the overall secondary structure element arrangement of PRPEG10 are shared with 
retroviral PRs (Figure 1). Disorder prediction revealed that the region in close proximity to the 
frameshift site (247–348) is unstructured. A region located near the catalytic D-S-G-A motif was 
predicted to adopt an α-helical conformation (Figure 1). This helical region presumably corresponds 
to an additional helical insert that is not present in most retroviral PRs but is present in equine 
infectious anemia virus (EIAV) protease [21], as well as in both human and yeast DNA-damage-
inducible 1 (Ddi1) proteins [22]. The C-terminal region of the protease domain was predicted to 
contain three β-sheets connected by short loops (Figure 1), implying that the homodimeric PRPEG10 
has a six-stranded dimer interface. 
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Figure 1. Structure-based sequence alignment of PRPEG10 with some retroviral and retroviral-like 
proteases. Secondary structures of yeast (2I1A.pdb) and human Ddi1 (3S8I.pdb), EAIV (1FMB.pdb), 
and HIV-1 (5HVP.pdb) PRs are indicated based on crystal structures, while the predicted secondary 
structural arrangement of PRPEG10 is shown based on in silico prediction. D-S/T-G-A active site motif 
residues are indicated by bold letters, the secondary structural elements are bold and underlined, 
while α-helices are colored in green. The color code of β-sheets in this figure corresponds to that of 
Figure 2—the N-terminal β-strands of HIV-1 and EIAV PRs, (which are involved in the formation of 
dimer interface) are red, while all other β-strands are blue. Triangles show PRPEG10 residues modified 
in this study to design D370A-fsRF1/RF2PEG10, D369A-RF1/RF2PEG10, and S371A-fsRF1/RF2PEG10 mutant 
proteins. 
A putative structure of homodimeric PRPEG10 was proposed by homology modeling in this study 
(Figure 2). The N- and C-terminal boundaries of PRPEG10 have not yet been experimentally 
determined; hence, the proposed termini of the protease domain are only approximate. The region 
upstream of the putative N-terminal residue (Ser346) and the proximity of the frameshift site (Gly319 
and Lys320 residues) were also predicted to be unstructured, which implied that these regions do not 
belong to the globular protease fold. The predicted presence of three β-sheets at the C-terminal end 
of PRPEG10 implies similarity to the dimer interfaces of Ddi1 proteins; therefore, their structures were 
used to build a six-stranded dimer interface for homodimeric PRPEG10. Additionally, Ddi1 proteins 
were found to be useful templates due to the presence of an additional helical insert, which is also 
present in EIAV PR [21]. The crystal structure of EIAV PR was used as a template to model closed 
conformational flap regions of PRPEG10, since the flaps of Ddi1 proteins are disordered in electron 
density maps [22] (Figure 2). However, template structures showed <20% sequence identity to 
PRPEG10; despite this, these proteins share high structural similarity [22]. 
 
Figure 2. The predicted folding pattern of PRPEG10 is similar to that of other homodimeric aspartic 
proteases. Overall structures represented here are based on crystal structures of HIV-1 PR (PDBID: 
7HVP), EIAV PR (PDBID: 1FMB), and human Ddi1 protease (PDBID: 3S8I), while the proposed model 
structure of PRPEG10 is shown. Red arrows indicate additional helical inserts in the front views of PR 
structures (upper panel). Dimer interfaces of the PRs are enlarged in the bottom views of PR structures 
(lower panel); only the N- and C-terminal β-sheets are colored (red and blue, respectively). 
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Based on the results of secondary structure prediction and homology modeling, PRPEG10 shares 
its overall fold with retroviral PRs (Figure 2). The dimer interface of PRPEG10 was predicted to resemble 
those of Ddi1 proteins, and consists of only C-terminal β-sheets showing no alternation. In contrast, 
both the N- and C-terminal β-sheets are involved in the formation of the HIV-1 PR dimer interface, 
showing interdigitation (Figure 2). A putative C-terminal residue of the protease domain was 
predicted to be located near the third β-sheet, and the dimer interface was predicted to be not 
followed by a longer C-terminal extension, since no secondary structural elements were predicted for 
this region. The proposed model structure may be used to support the biochemical characterization 
of the protease, including mutation design and computational calculations. 
To inactivate PRPEG10, we mutated the catalytic aspartate to alanine to create a D370A mutant 
protein. Mutation of Thr to Ala in the D-T-G-A active-site motif of HIV-1 PR was previously reported 
to result in a virtually inactive enzyme, since the dimerization of monomers is inhibited due to the 
lack of the key “fireman’s grip” interactions [23]. To investigate whether PRPEG10 dimerization is 
similar to that of HIV-1 PR and to correlate the findings of in vitro experiments to the homology 
model, an S371A-fsRF1/RF2PEG10 mutant was also designed, in which the D-S-G-A catalytic motif’s Ser 
residue was mutated to Ala. 
Beside comparing the overall folding and secondary structural arrangement of PRPEG10 to that of 
retroviral or other retroviral-like proteases, we used the model structure to investigate the substrate 
binding sites of the enzyme. In our previous comparative studies, the mean cavity volumes of S1–S4 
substrate binding sites were calculated to determine the P1–P4 specificities of retroviral PRs, 
respectively [24,25]. Although in vitro specificity studies have not yet been performed for PRPEG10, 
results of in silico calculations can be used to compare the compositions of substrate binding sites to 
those of other PRs (Figure 3a). The volume of the S1 site of PRPEG10, which is composed of mainly 
hydrophobic residues, was determined to be similar to that of HIV-2 and Mason–Pfizer monkey virus 
(MPMV) PRs, and smaller than that of HIV-1 and EIAV PRs. However, retroviral PRs may show 
remarkable differences in the size of the S1 cavity and they were found to have similar preferences 
for Phe and Tyr residues in the P1 position [25]. In accordance with this, PRPEG10 may also potentially 
prefer to bind medium- or large-sized hydrophobic residues at the S1 site. The cavity volume of the 
S2 site of PRPEG10 resembles that of a group of proteases that exhibit preference for Ala and Cys at this 
position [25]. Similar to that of HIV-1 and EIAV PRs, the S2 cavity of PRPEG10 also consists of mainly 
hydrophobic residues. The S3 site of PRPEG10 was calculated to be large and contains exclusively 
hydrophilic residues, which implies a preference for polar P3 residues at this site. This is similar to 
the S3 sites of HIV-1 and EIAV PRs, which do not discriminate P3 substrate residues based on 
hydrophobicity [25]. Although the S4 pocket is less defined than the others due to its close proximity 
to the protein surface, its size was also calculated. PRPEG10 was found to have an average-sized S4 site, 
with a similar ratio of hydrophobic and hydrophilic residues to that of HIV-1 PR (Figure 3b). Results 
were used for the estimation of an autoproteolytic cleavage site, which is discussed below. 
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Figure 3. Comparison of mean cavity volumes and substrate binding site compositions. Mean cavity 
volumes (left graphs) and amino acid compositions (right tables) of substrate binding sites are shown 
for HIV-1, EIAV, and PEG10 proteases. Graphs represent the average volumes of most preferred 
residues plotted against the mean cavity volumes of the substrate binding sites. The most preferred 
residues and cavity volumes have been determined previously for retroviral proteases in vitro and in 
silico, respectively [24,25]. Black diamond symbols indicate values used for correlation analysis, while 
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opened diamonds show values that have been excluded from the correlation. Only mean cavity 
volumes are indicated for PRPEG10 binding sites (shown by red arrows), since the volumes of preferred 
residues have not been determined experimentally to date (a). Substrate binding site compositions of 
HIV-1 and EIAV PRs (*) were determined in previous studies [24,25] and structural alignment based 
on homology model structure was used to identify residues in the case of PRPEG10. Bold letters indicate 
that side-chain–side-chain interaction may occur. Residues were classified as follows: hydrophobic: 
A, V, I, L, F, W, C, M, P, and G; hydrophilic: S, T, N, Q, Y, and H; charged: D, E, K, and R (b). 
2.2. Proteolytic Activity of PRPEG10 
For the characterization of PRPEG10, a total of six protein variants were prepared (Figure 4a). In 
addition to RF1/RF2PEG10 and its frameshift mutant form (fsRF1/RF2PEG10), active site protease mutants 
were also studied (Figure 4a). 
 
Figure 4. Comparison of the studied forms of PEG10. Schematic structures of the PEG10 proteins 
designed in the present study. RF1 and RF2 are colored by green, the black triangles indicate the 
frameshift site, and red markings show the termination codons of the translation, while blue color 
highlights active site motif (a). Expression of different forms of RF1/RF2PEG10 in HEK293T cells was 
detected with anti-PEG10 antibody (b). 
All proteins were expressed in HEK293T cells, which were transfected by equal amounts of 
plasmid DNAs for each variant, while expression of the different PEG10 proteins was detected by 
Western blot (Figure 4b). Since the anti-PEG10 used for Western blot only targeted RF1PEG10 (1–325 
res), we could not detect RF2PEG10 alone. 
HEK293T cells have a low basal level of endogenous PEG10 expression according to the Human 
Protein Atlas database (https://www.proteinatlas.org). In agreement with this, the protein was not 
detected in HEK293T cells by Western blot; therefore, non-transfected cells were used as control. In 
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the lysates of cells transfected with RF1/RF2PEG10 plasmid, only RF1PEG10 was detectable, which 
indicated the previously described low frameshift efficiency [16] and proteolytic processing of the 
RF1/RF2PEG10 protein. For the D369A-RF1/RF2PEG10 mutant, the RF1/RF2PEG10 protein was also 
detectable, which implied that mutation of the protease’s active site prevented autoproteolysis 
(Figure 4b). 
To ensure overexpression of RF1/RF2PEG10 and explore the effects of active-site mutations on 
autoproteolysis, a frameshift variant (fsRF1/RF2PEG10) and active site mutants were also designed 
(D370A- and S371A-fsRF1/RF2PEG10) (Figure 5a). Following incubation of the lysate of cells 
overexpressing fsRF1/RF2PEG10, we observed the appearance of bands at ~45 kDa and ~37 kDa (Figure 
5a). These bands were thought to correspond to those processing fragments (PF1: ~45kDa; PF2: 
~37kDa) that resulted from the proteolytic activity of fsRF1/RF2PEG10 [15]. The autoproteolytic 
fragments were not detected for the catalytic aspartate mutant (D370A-fsRF1/RF2PEG10) protein, 
indicating that active site mutation abolished its proteolytic activity, supporting the hypothesis that 
PRPEG10 has maintained its ability for autoproteolysis during its evolution. Similar to the D370A 
mutation, the S371A mutation also resulted in the inactivation of PRPEG10 (Figure 5a). 
 
Figure 5. The appearance of cleavage fragments implies proteolytic activity of RF1/RF2PEG10. Lysates 
of cells transfected with fsRF1/RF2PEG10 or with active-site mutant fsRF1/RF2PEG10 were incubated at 37 
°C and then analyzed by Western blot. Upper bands indicate fsRF1/RF2PEG10 proteins, and lower bands 
indicate proteolytic fragments (PF1: ~45 kDa; PF2: ~37 kDa). Results are representative of three 
independent experiments (a). The lysate of cells overexpressing D370A-fsRF1/RF2PEG10 was incubated 
with the total cell lysate of non-transfected HEK293T cells (b). “+” denotes the presence, while “–“ 
denotes the absence of the given component. 
To exclude the possibility that the fsRF1/RF2PEG10 protein was processed in our experiments by 
cellular proteases of HEK293T cells, the lysate of cells overexpressing the D370A catalytic mutant 
protein was incubated with the lysate of non-transfected HEK293T cells. In this case, no proteolytic 
fragments were detected by Western blot, even after a long incubation time. This proved that PRPEG10 
was responsible for the observed processing of fsRF1/RF2PEG10 protein rather than cellular proteases 
(Figure 5b). 
In the experiments shown in Figure 5, a long incubation time (20 h) was applied to provide 
sufficient processing of the RF1/RF2 precursors, to prove the success of protease inactivation, and to 
ensure that active site mutants do not undergo self-proteolysis. In consideration, we applied a long 
incubation time for the samples in other experiments as well; however, we observed autoproteolysis 
even with a shorter incubation time (see later in section 2.5). 
2.3. Estimation of an Autoproteolytic Cleavage Site 
Computational calculations based on homology model structures may aid specificity studies 
[24,25], and together with the results of in vitro experiments can be used to predict possible cleavage 
site sequences. HIV-1 PR is the most studied retroviral protease, and several methods are available 
to predict its cleavage sites within target sequences; however, such predictions may be more 
problematic or less accurate for less-studied enzymes. While the autoproteolytic recognition 
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sequences of PRPEG10 are unknown and experimental specificity studies have not been yet performed, 
we used the proposed model structure to predict an autoproteolytic cleavage site within RF1/RF2PEG10. 
The difference between the molecular weight of the PF1 proteolytic fragment and RF1PEG10 
protein was estimated by analysis of Western blot images (Figure 6a), and was found to be between 
4 and 5 kDa. This difference implied the occurrence of a cleavage site between the capsid-like domain 
and the Zn-finger motif of RF1PEG10 (Figure 6b). In order to predict a possible cleavage site, volumes 
of P4–P1 residues were correlated with the calculated cavity volumes of S4–S1 sites, respectively (see 
cavity volumes in Figure 3). Correlation analysis using a 4-residue window (Figure 6c) revealed the 
highest value for the HHQVD*PTEPV sequence (Figure 6d), which may correspond to a potential 
cleavage site due to the following reasons: (i) the highest correlation was observed for this cleavage 
site if volumes of P4–P1 residues were correlated with those of S4–S1 cavities, respectively; (ii) Gln 
and Glu residues can be found in P3 and P3’ positions, respectively, which is in agreement with the 
hydrophilic residue composition of the S3 substrate binding cavity; and (iii) despite containing an 
unusual residue (Asp) in the P1 position, the proposed sequence resembles the type 1 retroviral 
protease cleavage sites [26], which also contain Pro at the site of cleavage (in the P1′ position). 
 
Figure 6. Estimation of the autoproteolytic region in fsRF1/RF2PEG10. To identify the region in 
fsRF1/RF2PEG10 where the autoproteolysis may occur, the molecular weight of PF1 was compared to 
that of RF1PEG10. A representative blot image of three independent experiments is shown (a). 
Approximately 4–5 kDa difference in the molecular weight indicated that RF1PEG10 may be cleaved 
prior to the frameshift site, between the C-terminal capsid-like domain and the Zn-finger motif (b). 
The sequence of RF1PEG10 was analyzed in order to identify a potential cleavage site in the region 
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between the capsid-like domain and the Zn-finger motif. The volumes of P4–P1 residues were 
correlated with the calculated cavity volumes of S4–S1 sites, respectively (see cavity volumes in Figure 
3). Each arrow shows a putative cleavage position for which a correlation coefficient (r2) has been 
determined. The highest values are shown in red. The calculated difference between RF1PEG10 and PF1 
is also shown for some cleavage positions. The dashed line shows the sequence for which the 
correlation analysis is shown in the graph (c). For PEG10, the graph shows the correlation between 
volumes of P4–P1 residues and S4–S1 cavities for the 266HQVD*PTEP273 cleavage site. For 
comparison, calculation was performed for the HIV-1 MA/CA cleavage site (SQNY*PIVQ) using the 
cavity volumes published previously (d) [24,25]. 
2.4. Ubiquitination of PEG10 
Ubiquitination of D370A-fsRF1/RF2PEG10 was detected by Western blot using anti-ubiquitin 
antibody (Figure 7), proving that the protein undergoes ubiquitination. The molecular weight of the 
protein was estimated in relation to molecular weight markers after SDS-PAGE, and the obtained 
difference implied di-ubiquitination of the protein (the molecular weight of ubiquitin is ~8.5 kDa). 
 
Figure 7. Western blot analysis revealed ubiquitination of PEG10. To evaluate whether the PEG10 
protein undergoes ubiquitination, D370A-fsRF1/RF2PEG10 was purified and immunoblotted using anti-
PEG10 and anti-ubiquitin primary antibodies. Total cell lysates of HEK293T cells were used as control 
and underwent the same technical procedures as D370A-fsRF1/RF2PEG10 (cell lysis, Ni-chelate affinity 
chromatography). 
In addition, we suppose that the ~8 kDa difference observed between the molecular weights of 
the PF1 and PF2 product bands (Figure 5a) may be the result of ubiquitination; accordingly, the ~45 
kDa cleavage fragment may correspond the ubiquitinated form of the ~37 kDa product. The ~37 kDa 
product containing the intact N-terminal region of RF1 had relatively lower band intensity compared 
to the other band (~45 kDa), both in the previous report [15] and the herein described blot image. To 
prove this, the eukaryotic expression system needs to be applied for protein expression, because 
Escherichia coli cells lack an ubiquitination system. Moreover, proteolytic fragments may be hardly 
detectable in total cell lysates, where a significant amount of ubiquitinated cellular protein may also 
be detected. 
2.5. Trans activity of PRPEG10 
To test the catalytic activity of PRPEG10, we designed a His6-MBP-fsRF1/RF2PEG10-mTurquoise2 
protein substrate containing the 1–345 residues of the full-length human fsRF1/RF2PEG10 protein (MBP 
denotes maltose binding protein). This region was believed to contain putative autoproteolytic site(s) 
of PRPEG10 (see Figure 6b). The His6-MBP-fsRF1/RF2PEG10-mTurquoise2 protein was expressed in 
BL21(DE3) Escherichia coli cells, and after its purification with nickel-nitrilotriacetic acid (Ni-NTA) 
magnetic agarose beads, the purified recombinant protein was applied as a substrate for PRPEG10. Even 
in the presence of multiple possible cleavage sites in the recombinant protein, cleavage reactions 
revealed no proteolysis of the substrate, which implied the lack of trans activity of the protease 
(Figure 8b). In parallel with the cleavage reactions, autoproteolysis was also studied at all time points, 
and the results indicated autoproteolytic activity (cis activity) of PRPEG10 (Figure 8a). A control 
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cleavage reaction was also performed by TEV PR, and the effective cleavage indicated proper folding 
of the recombinant substrate (Figure 8b). Based on these results, we suppose that autoproteolysis of 
the RF1/RF2PEG10 protein may block the trans activity of PRPEG10. 
To investigate the protease activity of the recombinant protein, fsRF1/RF2PEG10 was expressed in 
a bacterial expression system as well, but we failed to detect proteolytic activity of the purified 
protein. 
 
Figure 8. PRPEG10 does not exhibit trans activity. The lysate of fsRF1/RF2PEG10-transfected cells was 
dialyzed against storage buffer and later incubated with a recombinant protein substrate (S) 
containing potential autolytic sites. For Western blot, anti-PEG10 antibody was applied to follow the 
autoproteolysis of fsRF1/RF2PEG10. Sample compositions are shown at the bottom of the figure; samples 
shown in figure part A did not contain recombinant protein substrate (a). Furthermore, anti-MBP 
antiserum was used to follow changes in the full-length recombinant protein. The recombinant 
substrate was digested with TEV PR (S+TEV) as well. The product is indicated with the letter P (b). 
Results are representative of three independent experiments. “+” denotes the presence, while “–“ 
denotes the absence of the given component. 
2.6. Effect of pH on Autoprocessing 
The dependence of fsRF1/RF2PEG10 autoproteolytic activity on pH was also studied in the pH 
range of 5–8 (Figure 9). The appearance of the PF1 proteolytic cleavage product was followed by 
detection of fsRF1/RF2PEG10 using Western blot. We observed increasing band intensities at ≥ 6.0 pH, 
while lower pH was found to be suboptimal for PRPEG10. The optimal pH for the autoprocessing of 
fsRF1/RF2PEG10 was close to neutral (between 6.9 and 7.4) (Figure 9a). The D370A mutant fsRF1/RF2PEG10 
was used as control, and as expected, it exhibited no autoproteolytic activity (Figure 9b). 
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Figure 9. Processing of fsRF1/RF2PEG10 is dependent on pH. Autoprocessing of fsRF1/RF2PEG10 (a) and 
D370A-fsRF1/RF2PEG10 (b) was studied in META buffer (pH range: 5.4–7.9). Release of PF1 
autoproteolytic fragment was not observed for the protease mutant (lower blot image). Results are 
representative of two independent experiments. 
2.7. Effects of Protease Inhibitors on Autoprocessing 
Using in vitro experiments, we assessed whether pepstatin A, lopinavir, nelfinavir, saquinavir, 
darunavir, and tipranavir PR inhibitors are able to inhibit PRPEG10 self-processing. The control sample 
contained only DMSO, since the inhibitors were dissolved in this organic solvent. None of the tested 
inhibitors showed significant inhibition of the protease activity; the formation of PF1 product was 
comparable to that in the control sample (Figure 10). 
 
Figure 10. PRPEG10 autoproteolysis is not inhibited by the tested inhibitors. Autoproteolysis of 
fsRF1/RF2PEG10 was studied in vitro in the presence of the PR inhibitors using pepsatin A, lopinavir, 
nelfinavir, saquinavir, darunavir, and tipranavir. Each inhibitor was dissolved in DMSO and applied 
at a 10 µM final concentration. Results were obtained by Western blot using anti-PEG10 antibody. 
Results are representative of two independent experiments. “+” denotes the presence, while “–“ 
denotes the absence of the given component. 
2.8. Effect on Cellular Proliferation and Viability 
Involvement of PEG10 in carcinogenesis in multiple cell lines had already been reported [3–11]; 
therefore, after investigating the characteristics of PEG10 autoproteolysis, the potential role of PRPEG10 
in cellular proliferation and the effect of its overexpression on cell viability were also studied. 
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Overexpression of fsRF1/RF2PEG10 was found to significantly decrease the viability of HEK293T 
and HaCaT cells maintained in optimal growth conditions compared to the mock control. In the case 
of the inactive protease mutant D370A-fsRF1/RF2PEG10, no significant change in cell viability was 
observed compared to the mock control (Figure 11). 
 
Figure 11. fsRF1/RF2PEG10 decreases the viability of HEK293T and HaCaT cells. The role of PRPEG10 in 
the cell viability of HEK293T (a) and HaCaT cells (b) was investigated using the MTT assay, which 
was performed 1 day after transfection. Mock control cells were transfected with pQE-TriSystem 
plasmid. Significance values were determined as compared to mock control, otherwise they are 
indicated. Note: ****p ≤ 0.0001; ***p  ≤  0.001; **p  ≤  0.01; *p ≤ 0.05; ns = non-significant (p > 0.05). Error 
bars represent SD (n ≥ 4). 
In agreement with the results of previous studies, we found that overexpression of PEG10 did 
not result in remarkable promotion of cell growth in HEK293T cells [4]. However, when we compared 
proliferation of cells overexpressing fsRF1/RF2PEG10 or D370A-fsRF1/RF2PEG10, a significant difference 
was observed. In the case of fsRF1/RF2PEG10, the percentage of Ki67-positive HEK293T cells was 
significantly higher compared to those expressing the inactive protease mutant, suggesting that 
PRPEG10 plays an active role in the promotion of proliferation. We also investigated the rate of cell 
proliferation in HaCaT cells; however, as these cells undergo rapid division (doubling time of 24 h), 
no significant difference was observed (Figure 12). 
 
Figure 12. PRPEG10 influences the proliferation of HEK293T cells. In the cell proliferation assay, 
HEK293T (a) and HaCaT cells (b) were stained with FITC-conjugated anti-Ki67 antibody, which was 
detected using a flow cytometer (FACS). Significance values were determined as compared to mock 
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control, otherwise they are indicated. Note: *p  ≤  0.05; ns = non-significant (p > 0.05). Error bars 
represent SD (n ≥ 2). 
The characteristics of the protease mutant PRPEG10 had not been previously investigated in detail. 
Studies that revealed the oncogenic potential of PEG10 focused on RF1PEG10, while RF2PEG10 remained 
understudied. Based on our results, we can conclude that both RF1PEG10 and RF2PEG10 play significant 
roles in cell viability and proliferation in HEK293T and HaCaT cells. We hypothesize that 
RF1/RF2PEG10 may neutralize the oncogenic potential of RF1PEG10 by a self-inactivation mechanism. 
3. Discussion 
In this study, we investigated the structural and biochemical characteristics of the aspartic 
protease domain encoded by the human retrotransposon-derived gene PEG10. 
The three-dimensional structure of PRPEG10 has not been solved experimentally to date; therefore, 
in silico prediction algorithms were applied to estimate structural characteristics of the protease 
structure. Based on the results of secondary structure prediction and homology modeling, PRPEG10 
shares its overall fold with those of retroviral PRs (Figure 2). PRPEG10 was found to show the highest 
sequence and structural similarity with DNA-damage-inducible 2 (Ddi2) and Ddi1 PRs [22,27,28]; 
each of these retroviral-like PRs contains an additional helical insert and has a six-stranded dimer 
interface organization, which was not found to be characteristic of retroviral PRs [29]. In addition, 
the D-S-G-A active site motif of human PRPEG10 is also identical to that of human Ddi1 and Ddi2 PRs, 
but this consensus motif is followed by a Ser residue (D-S-G-A-S) in PRPEG10 (Figure 1). Ser in this 
position is not characteristic of retroviral or Ddi1/Ddi2 PRs [29] but can be found in the Ty1 
retrotransposon PR [30]. The D-T/S-G-A active site motif of most retroviral PRs is followed by an Asp 
residue, but in contrast with this Asp residue, a Ser in this position does not enable salt-bridge 
formation between PRPEG10 subunits. In the sequence motif of the consensus helix, retroviral PRs 
(excepting spumaretrovirus PRs) contain the G-R-N motif, but similarly to Ddi1 and Ddi2 proteins, 
PRPEG10 also contains a different sequence (G-V-R) in this helix, and thus lacks the corresponding 
interactions that are provided by the Arg residue of the G-R-N motif [29]. Structural analysis of 
retroviral and Ddi1 and Ddi2 PRs revealed correlation between the dimer interface organization and 
the intermonomeric contacts [29]. No data are available for in vitro dimer stability of PRPEG10, but high 
structural similarity implies that its dimer stability may be comparable with those of Ddi1/Ddi2 PRs 
and may be lower than that of HIV-1 PR. 
To investigate the biochemical characteristics of PRPEG10 in vitro, we expressed different forms of 
PEG10 in HEK293T mammalian cell line (Figure 4a), and detected these in total cell lysates by 
Western blot analysis (Figure 4b). We observed two proteolytic fragments (PF1: ~ 45 kDa and PF2: ~ 
37kDa); the ~37 kDa product was previously found to contain the intact N-terminus of the protein 
and is part of RF1 [15]. Proteolytic fragments did not appear when PEG10 harboring an active-site 
mutation of PRPEG10 was expressed (Figure 5). As observed in the case of HIV-1 PR, D25A mutation 
resulted in complete inactivation of the enzyme, whereas the T26A mutant showed only residual 
proteolytic activity. While the mutant HIV-1 PR was virtually monomeric, traces of active dimers 
were believed to be formed upon interaction with the substrate [23]. In accordance with this, our 
results imply that PRPEG10 has the ability to dimerize; this ability was abolished by the S371A mutation. 
Results of our in vitro experiments are in good agreement with the predicted structure and prove the 
essential role of the S371 residue in the dimerization of PRPEG10, which depends on “fireman’s grip” 
interactions, similar to HIV-1 PR. 
Previous studies on PEG10′s protease activity implied multiple cleavages within human and 
mouse PEG10, but the cleavage pattern varied among different cell lines and tissues [12,15,31]. We 
only observed a single cleavage product (PF1) when anti-PEG10 antibody was used for the detection 
of proteolytic fragments in HEK293T cells. The molecular weight of PF1 was estimated based on 
Western blot images and indicated that autoproteolysis may occur prior to the frameshift site, 
between the capsid-like domain and the Zn-finger motif. The compositions and cavity volumes of the 
substrate binding sites were determined based on the homology model structure (Figure 3), and the 
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results of in vitro and in silico experiments were used to estimate a potential cleavage position. The 
highest probability was predicted for the HHQVD*PTEPV cleavage site (Figure 6), which does not 
resemble most cleavage site sequences of retroviral PRs. Although the presence of an aspartate 
residue in the P1 position is not characteristic of retroviral PR cleavage sites, it is not unique. For 
example, the naturally occurring nucleocapsid–protease cleavage site of Walley epidermal 
hyperplasia virus (WDSV) PR contains a P1-Asp residue (TYPAD*PIDC) [26], and bovine leukemia 
virus (BLV) PR was also found to efficiently cleave a peptide representing a P1-substituted analogue 
of the HTLV-1 capsid–nucleocapsid cleavage-site (KTKVD*VVQPK) [32]. Structural analysis of BLV 
and human T-cell leukemia virus type I (HTLV-1) PRs revealed that both enzymes have mainly 
hydrophobic S1 binding cavities, which consist of identical residues [25]. In contrast, the P1-Asp-
substituted substrate was cleaved efficiently by BLV protease, but not by HTLV-1 PR [25]. This shows 
that estimation of cleavage positions based purely on the volumes of cleavage site residues and 
substrate binding cavities should only be considered approximate. 
The applied small-scale eukaryotic expression system was found to be not suitable enough to 
produce the protein in sufficient amounts for cleavage site identification; thus, fsRF1/RF2PEG10 was 
expressed in a bacterial expression system. Similar to other retroviral-like proteases—especially 
recombinant human Ddi2 [27] and S. cerevisiae Ddi1 [28] PRs—we also failed to detect the proteolytic 
activity of the bacterially expressed purified protein. As has already been proposed for Ddi1 and 
Ddi2 PRs [27,28], putative-specific factors or determinants may be necessary for the activation of the 
protease, which would probably not be present in the sample after protein purification. Therefore, 
identification of the autoproteolytic cleavage positions of PEG10 remains to be identified. 
Our data imply low catalytic efficiency of PRPEG10, but detailed comparison cannot be made due 
to the limited data on the catalytic efficiencies of retroviral-like proteases. To date, the proteolytic 
activity of a recombinant protein was proven in vitro only for Leishmania major Ddi1 [33] and 
Saccharomyces cerevisiae Ty1 retroviral-like proteases [30], while catalytic efficiency was determined 
only for the latter one. The structural characteristics of PRPEG10 indicate high similarity with other 
retroviral-like proteases; thus, the dimer stability of PRPEG10 is potentially lower than that of most 
retroviral proteases [31], and is more comparable to that of retroviral-like proteases. For example, Ty1 
PR was found to possess trans activity and has very low specific activity as compared to retroviral 
proteases (e.g., HIV-1, HTLV-1, BLV, and MMLV) [30]. Due to the limited data, future studies need 
to reveal whether all human retroviral-like proteases (including PEG10, Ddi1, and Ddi2) have lower 
specific activity than retroviral proteases. 
Activity was not detected when a recombinant protein containing putative autoproteolytic sites 
was used as the substrate; the lack of trans activity indicated a self-inactivation mechanism for 
PRPEG10. The suspected self-inactivation mechanism has already been observed for alphavirus capsid 
PRs [34]. In these viruses, the nascent structural polyprotein contains an intramolecular 
(chymotrypsin-like) serine protease that possesses cis activity. As part of polyprotein maturation, 
self-cleavage occurs, leading to the release of the capsid. This autoproteolytic event is a perquisite for 
capsid assembly and results in PR inactivation. After self-cleavage, the conserved P1 residue of the 
cleavage site blocks the trans activity by interacting with the catalytic center [34]. Self-inactivation 
has also been described for the capsid protease of the Aura virus, Chikungunya virus [35], Sindbis 
virus [36], and Semliki Forest virus [37], but has not been previously reported in the case of retroviral 
or retroviral-like PRs. A possible mechanism for blocking trans activity may be caused by a crystal 
structure of the Ddi1 of Saccharomyces cerevisiae [28]. In this structure, the N-terminal region of the 
homodimeric PR interacts with the active site of the adjacent asymmetric unit as a pseudo-substrate. 
Although this was considered to be caused by a crystallization artefact, this reveals a possible mode 
of substrate engagement [28]. We assume that this binding mode may represent a possible mode of 
inactivation. In this case, the autoproteolytic fragments may interact with the active site of PRPEG10, 
blocking the trans activity. However, future studies are needed to explore whether inter- or 
intramolecular events are involved in the self-inactivation mechanism. 
We detected a difference between the calculated (73 kDa) and observed (~95 kDa) molecular 
weights of the overexpressed fsRF1/RF2PEG10 protein (Figures 4–10), which implies post-translational 
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protein modification [12,15]. The difference in the molecular weight is attributed to ubiquitination of 
RF1/RF2PEG10, which is supported by the fact that ubiquitination of PEG10 has already been indicated 
based on its interaction with the E3 ubiquitin-protein ligase SIAH1 protein [4]. Furthermore, 
quantitative proteomic analyses have reported this post-translational modification [38–41]. 
Ubiquitination sites of PEG10 are listed in the PhosphoSite database (http://www.phosphosite.org); 
our in silico predictions also indicated the presences of putative ubiquitination sites with high 
confidence (Table S1). Taking into consideration the above-mentioned findings, we assume that the 
differences in molecular weights of PF1 and PF2 may also be explained by ubiquitination; however, 
this requires further validation using co-immunoprecipitation techniques in future experiments. 
PRPEG10 exhibits similarities to other retroviral-like aspartic PRs; however, there are only few 
studies on the sensitivities of these PRs towards HIV PR inhibitors. Of the tested inhibitors, pepstatin 
A and saquinavir failed to inhibit the autoproteolytic activity of retroviral-like aspartic protease 1 
(ASPRV1), based on literature data [42]. In the case of human Ddi2 protein, isothermal titration 
calorimetry (ITC) measurements proved that several HIV PR inhibitors, including saquinavir, 
nelfinavir, darunavir, and acetyl-pepstatin, were unable to bind to the protein, and thus were 
ineffective against the Ddi2 PR [43]. Recently, human endogenous retrovirus-K (HERV-K) PR was 
found to be sensitive to darunavir and lopinavir [44]; however, its structure is more similar to that of 
HIV-1 PR than to those of PEG10, ASPRV1, and Ddi2 PRs. These data suggest that most HIV PR 
inhibitors have only weak inhibitory potential against retroviral-like human PRs or are unable to 
inhibit these enzymes. This implies that for an effective inhibition of PRPEG10 and its autoproteolytic 
function, specific inhibitors need to be designed and tested in the future. However, autoproteolysis 
was not inhibited by the panel of PR inhibitors (Figure 10), we found that self-processing is dependent 
on the pH (Figure 9), and the optimal pH is close to neutral (6.9–7.4), which is similar to the optimum 
pH for human foamy virus proteinase (6.6) [45]. 
To further elucidate the role of PRPEG10 in the function of PEG10, cell culture experiments were 
performed, which revealed that PRPEG10 plays an important role in the regulation of cell viability and 
proliferation (Figures 11 and 12). Transfection of cells with fsRF1/RF2PEG10 harboring wild-type PRPEG10 
resulted in a significant increase in cellular proliferation compared to cells overexpressing the 
catalytically inactive protease, at least in the HEK293T cell line. Notably, PRPEG10 appeared to decrease 
cell viability, since transfection of cells with fsRF1/RF2PEG10 led to a decrease in cell viability by > 60%. 
This effect was reversed when we inactivated PRPEG10 with the D370A mutation. Others have reported 
that the viability of Alexander and Huh7 cells was also adversely affected by the suppression of 
endogenous PEG10 expression, unlike in SNU423 cells, which do not express the endogenous protein 
[4]. The contribution of PEG10 to regulation of cell viability and proliferation has already been 
studied previously by either overexpressing recombinant PEG10 in transfected cells [4,9,12] or at the 
level of the endogenous protein (e.g., by downregulating expression by siRNAs) [8,10,11]. While the 
effects of a recombinant protein on cell viability and proliferation may be different as compared to 
the endogenous protein, the results obtained by different methods are comparable and reveal the 
oncogenic potential of PEG10. In agreement with this, in this work we aimed to study the protease 
activity of PEG10, and we think that the comparison of results obtained for the overexpressed 
recombinant wild-type and mutant proteins can provide valuable information about protease 
function. 
While the association between PEG10 and malignancies had already been reported [3–11], little 
is known about the function of PRPEG10. We demonstrated that PRPEG10 exhibits autoproteolytic 
activity, and is indeed involved in the cyto-proliferative effect observed when PEG10 is 
overexpressed, at least in HEK293T cell line. Although the precise mechanism by which PRPEG10 is 
involved in the induction of cellular proliferation is unclear, we hypothesize that the downregulation 
of pro-apoptotic pathways mediated by PEG10 is dependent on a functional protease domain, which 
may facilitate this interaction in a direct or indirect manner, the details of which should be 
investigated in the future. 
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4. Materials and Methods 
4.1. In Silico Analysis 
Secondary structure prediction was performed using the Jpred4 server [43] based on the 
sequence of PRPEG10 (UniProtKB: Q86TG7). Disorder prediction was performed using the IUPred web 
server [46]. Modeller9v13 [47] was used to prepare a homology model for the 346–477 region of 
RF1/RF2PEG10. Crystal structures of EIAV protease (PDBID: 1FMB) [21] and human (PDBID: 3S8I) and 
yeast (PDBID: 2I1A) Ddi1 proteins [22] were used as templates. Molecular visualizations were 
performed using the PyMOL Molecular Graphics System (version 1.3; Schrödinger, LLC). The mean 
cavity volumes of S1–S4 substrate binding sites were calculated for PRPEG10 using the previously 
described method [24,25]. Ubiquitination of human PEG10 was predicted by UbiSite 
(http://csb.cse.yzu.edu.tw/UbiSite/prediction.php) [48], BDM-PUB: Prediction of Ubiquitination sites 
with Bayesian Discriminant Method (http://bdmpub.biocuckoo.org), and UbPred (predictor of 
protein ubiquitination sites) (http://www.ubpred.org/cgi-bin/ubpred/ubpred.cgi) [49] web servers, 
using default parameters. 
4.2. Cloning 
The PEG10 human cDNA sequence (clone name hh04271) was obtained from Kazusa DNA 
Research Institute (Kisarazu, Japan). The vector (pQE-TriSystem) for expression of C-terminally 
8×His-tagged proteins was a kind gift from Zoltán Papp at the Division of Clinical Physiology, 
Institute of Cardiology, Faculty of Medicine, University of Debrecen. The cDNA sequences encoding 
RF1PEG10 (1–325 res), RF2PEG10 (320–626 res), and RF1/RF2PEG10 (1–626 res) were cloned into a HindIII 
and XhoI enzyme-cleaved pQE-TriSystem expression vector. As the PEG10 cDNA sequence contains 
an XhoI restriction endonuclease cleavage site, it was mutated to facilitate cloning of the sequence. 
Insertional mutagenesis was performed in the frameshift site of the sequence encoding RF1/RF2PEG10 
by insertion of a single adenine into the G-GGA-AAC “slippery” heptanucleotide sequence (G- GGA-
AAA-C, inserted nucleotide underlined) to enable transcription of the RF1/RF2PEG10-encoding mRNA 
(fsRF1/RF2PEG10). A thrombin cleavage site was designed after the PEG10-encoding sequences to 
facilitate removal of the polyhistidine tag from the fusion protein. The 1878-bp frameshift mutant 
RF1/RF2PEG10, followed by the sequence encoding the thrombin cleavage site, was cloned into the 
plasmid. The sequences encoding the RF1PEG10-thrombin cleavage site, the RF2PEG10-thrombin cleavage 
site, or the RF1/RF2PEG10-thrombin cleavage site were amplified in the initial PCR step, while the 
second PCR reaction was used to create a 3′XhoI restriction site. The inserts were amplified using 
PCR (iCycler Thermal Cycler, Bio-Rad, Hercules, CA, USA). Both the amplified fragments and the 
vector were digested with HindIII and XhoI restriction endonucleases and were extracted from 
agarose gel using a gel extraction kit (ISOLATE II PCR and Gel Kit, BIOLINE) after separation by 
electrophoresis. For ligation, T4 DNA ligase was used with a vector/insert molar ratio of 1:5. To 
predict the molecular weight of the C-terminal His-tagged PEG10 proteins, we used a freely available 
protein molecular weight calculator (http://www.bioinformatics.org/sms/prot_mw.html, date of last 
accession: June 2017). D369A, D370A, S371A, and XhoI endonuclease cleavage site mutations in the 
PEG10 sequence were generated using a QuikChange mutagenesis kit (Agilent Technologies, Santa 
Clara, CA, USA) according to the manufacturer’s instruction. Sequencing was performed using gene- 
and vector-specific primers and the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, Foster City, CA, USA). Oligonucleotide sequences are shown in Table S2. 
4.3. Transfection of HEK293T Cells 
HEK293T cells (Invitrogen, Carlsbad, CA, USA) were cultured in T-75 flasks in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 1% penicillin-streptomycin, 1% glutamine, 
and 10% fetal bovine serum (FBS), and incubated at 37 °C and 5% CO2. Cells were transfected with 
PEG10 constructs (14 µg DNA) at 60% confluency using a polyethylenimine (PEI) transfection 
protocol [50]. After transfection, the cells were incubated in DMEM containing no antibiotics and FBS. 
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After 5 h of incubation, fresh medium (supplemented with 10% FBS, 1% penicillin-streptomycin, 1% 
glutamine) was added to cells, and the cells were further incubated overnight. We used pQE-
TriSystem plasmid DNA as a mock control. 
4.4. Lysis of PEG10-Transfected HEK293T Cells 
Cells were trypsinized and collected by centrifugation (130× g, 8 min, room temperature) 24 h 
after transfection. The pellet was resuspended in 500 µL of phosphate-buffered saline containing 
protease inhibitor cocktail (complete EDTA-free Protease Inhibitor Tablet, ROCHE, St. Louis, MO, 
USA). The pellets were lysed by sonication (Branson Sonifer 450, duty cycle 30 %, output control 4) 
for 3 × 10 s. Cell lysates were then centrifuged at 16,000× g for 15 min at 4 °C to remove cellular debris. 
For the comparison of expressed PEG10 proteins, 30 µL aliquots of the supernatants were analyzed 
by Western blot. 
4.5. Analysis of Proteolytic Activity 
Following transfection with either fsRF1/RF2PEG10 or active-site mutant fsRF1/RF2PEG10, HEK293T 
cells were incubated for 48 h and the medium was replaced after 24 h. Next, the cellular pellet was 
collected and lysed as described above (see “Lysis of PEG10-transfected HEK293T cells”). After cell 
lysis and centrifugation, supernatants were dialyzed overnight against storage buffer (20 mM 
piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), 1 mM EDTA, 100 mM NaCl, 10% glycerol, 0.5% 
Nonidet P-40, 2 mM DTT, pH 7.0). Protease inhibitor cocktail (20 µL of 7× stock solution) was also 
added to 120 µL lysate to inhibit the proteolysis of the protein of interest by serine, cysteine, and 
metalloproteases present in the cellular extract. The proteolytic activity of fsRF1/RF2PEG10 was assessed 
by incubating the total cell lysates of transfected cells for 20 h at 37 °C. For the “0 h” sample, the 
collected cell lysate was frozen immediately at −20 °C. 
To investigate the susceptibility of a recombinant protein substrate for cleavage by PRPEG10, the 
total cell lysate of transfected HEK293T cells expressing fsRF1/RF2PEG10 protein was incubated with 
His6-MBP-fsRF1/RF2PEG10(1-345)-mTurquoise2 fusion protein in storage buffer for 24 h at 37 °C. The 
cleavage reaction was followed by Western blot using anti-MBP antiserum (E8030S, New England 
Biolabs, Ipswich, MA, USA) and anti-PEG10 antibody (SAB1400438-50UG; Sigma-Aldrich, St. Louis, 
MO, USA). 
4.6. Recombinant Protein Substrate Preparation 
For preparation of a recombinant fusion protein substrate containing the 1–345 residues of the 
full-length fsRF1/RF2PEG10 protein (His6-MBP-fsRF1/RF2PEG10 (1-345)-mTurquoise2), we used a slightly 
modified version of the previously described method [51]. The introduced changes are detailed 
below. 
A pGEX-4T-3 expression plasmid containing the codon-optimized coding sequence of the 
fsRF1/RF2PEG10 protein was obtained from GenScript, and the pDest-His6-MBP-mTurquoise2 bacterial 
expression plasmid was used from the in-house stock [51] The coding sequence of the 1–345 region 
of the fsRF1/RF2PEG10 protein was amplified using PCR, and both the amplicon and pDest-His6-MBP-
mTurquoise2 plasmid were digested with PacI and NheI restriction endonucleases followed by 
ligation. The plasmid was transformed into BL21(DE3) Escherichia coli cells, and then the His6-MBP-
fsRF1/RF2PEG10(1–345)-mTurquoise2 protein substrate was expressed at 16 °C for 6 h. After cell lysis, 
the protein substrate was purified by Ni-NTA magnetic agarose beads (Qiagen, Hilden, Germany), 
after which the buffer was changed to modified storage buffer (20 mM PIPES, 100 mM NaCl, 0.05% 
Tween20, pH 7.0) using 0.5 mL 10K Amicon Ultra centrifugal filter tubes (Merck-Millipore, 
Burlington, MA, USA). The purified recombinant protein was applied as the substrate to test the 
proteolytic activity of PRPEG10. 
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4.7. Western Blot Analysis 
Samples were prepared for Western blot as described in the Section 4.5. Protein samples 
subjected for the detection of ubiquitination were purified with Ni-chelate affinity chromatography 
(HisTrap HP column, GE Healthcare; ÄKTA prime liquid chromatograph, Amersham Biosciences, 
Little Chalfont, UK). The SDS loading dye was added to the samples and the mixtures were boiled at 
95 °C for 10 min, followed by brief centrifugation. Samples were then loaded onto a 14% SDS 
polyacrylamide gel. Following SDS-PAGE electrophoresis, proteins were transferred onto a 
nitrocellulose membrane at 100 V for 70 min. The membrane was blocked by 5 % dry milk in Tris-
buffered saline (TBS, pH 7.5) for 1 h at room temperature, followed by incubation with the antibodies. 
Mouse anti-PEG10 polyclonal antibody (SAB1400438-50UG; Sigma-Aldrich, St. Louis, MO, USA) was 
applied in a 1:2000 dilution, a rabbit anti-ubiquitin polyclonal antibody (Z0458; Dako Cytomation, 
Glostrup, Denmark) in a 1:500 dilution, and a rabbit anti-MBP antiserum (E8030S, New England 
Biolabs, Ipswich, Massachusetts, USA) in a 1:20,000 dilution. Rabbit anti-GAPDH antibody (G9545; 
Sigma-Aldrich, MO, USA) was applied in a 1:15,000 dilution. Primary antibodies were diluted in Tris-
buffered saline complemented with Tween20 (TTBS) containing 0.1 % dry milk and were incubated 
at 4 °C overnight. The membranes were washed three times with TTBS for 15 min and were then 
incubated with polyclonal anti-mouse (A4416; Sigma-Aldrich, MO, USA) or anti-rabbit (170–6515; 
Bio-Rad, CA, USA) secondary antibodies for 1 h at room temperature. The membranes were 
subsequently washed a further three times with TTBS. Proteins were detected using SuperSignal 
West Pico chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA). 
4.8. Determination of pH Optimum for PRPEG10 
Effect of pH on PRPEG10 activity was measured in META buffer (100 mM 2-(N-morpholino)-
ethanesulfonic acid (MES), 200 mM Tris, 100 mM Na-acetate, 2 M NaCl). Following transfection of 
cells, 100 µL of cell lysate was dialyzed against storage buffer (pH 7.0) for 3 h and then incubated at 
37 °C for 20 h in a 1:1 volume ratio of a series of META buffers with pH values ranging from 5.0 to 
8.0. The pH values of the reactions mixtures were determined to be 5.4, 5.7, 6.0, 6.5, 6.9, 7.4, and 7.9. 
4.9. In Vitro Inhibition of PRPEG10 
Pepstatin A, lopinavir, nelfinavir, saquinavir, darunavir, and tipranavir (NIH AIDS Reagent 
Program) dissolved in dimethylsulfoxide (DMSO, Sigma-Aldrich, MO, USA) were used for the 
inhibition of PRPEG10. The reaction mixtures contained the lysate of fsRF1/RF2PEG10-transfected cells, 
which was dialyzed against storage buffer. HIV inhibitors were added to a final concentration of 10 
µM, followed by incubation at 37 °C for 20 h. Only DMSO was added to the control sample. The 
reactions were terminated by the addition of SDS loading dye, and the mixtures were boiled at 95 °C 
for 10 min and centrifuged briefly before Western blot analysis. 
4.10. Cell Viability Assay 
HEK293T and HaCaT cells were seeded at a density of 10,000 cells per well (~70–80% confluence) 
in 96-well plates 16 h before treatment. For transfection of the cells, Lipofectamine LTX&PLUS™ 
reagent (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer’s instructions. The 
plasmid DNA (100 ng/well) and the Lipofectamine reagent (0.5 µL/well) were also diluted in Opti-
MEM medium. After incubation for 5 min, the DNA was mixed with the diluted Lipofectamine in a 
1:1 volume ratio. The DNA–lipid mixture was incubated for 20 min at room temperature. The cell 
culture medium was changed to fresh Opti-MEM (90 µL) in each well, and after addition of the pre-
incubated mixture the cells were further incubated for 5 h, then the transfection medium was replaced 
with fresh DMEM. Cell viability was determined by adding 1 mM of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Invitrogen, Carlsbad, CA, USA) to the cells that were incubated 
at 37 °C for 4 h. Then, MTT formazan crystals were dissolved using DMSO (Sigma-Aldrich, MO, 
USA), followed by re-incubation for 10 min. Absorbance values were measured at 544 nm using an 
automatic microplate reader (Wallac 1420 Victor2, Wallac Oy, Turku, Finland). HEK293T cells 
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transfected with a pQE-TriSystem plasmid were used as mock control, whereas the efficiency of 
transfection was determined by measuring fluorescence of cells transfected with a pQE-TriSystem-
GFP plasmid. 
4.11. Analysis of Cell Proliferation by Flow Cytometry 
HEK293T and HaCaT cells maintained in DMEM (supplemented with 1% penicillin-
streptomycin, 1% glutamine, and 10% FBS) were plated in 6-well plates at a density of 3 × 105 
cells/well 24 h before transfection. Cells maintained in Opti-MEM medium lacking antibiotics were 
transfected with fsRF1/RF2PEG10 or D370A-fsRF1/RF2PEG10 DNA, using Lipofectamine LTX&PLUS™ 
reagent (Invitrogen, CA, USA) according to the manufacturer’s protocol. Then, 5 µL/well 
Lipofectamine reagent and 3 µg/well plasmid DNA were diluted in Opti-MEM medium and 
incubated for 5 min. After incubation, the DNA and the Lipofectamine were mixed (volume ratio of 
1:1). In order to form the DNA-lipid complex, the solution was incubated again for 20 min. The 
incubated solution was added to the cells in 750 µL Opti-MEM dropwise and incubated for 5 h. For 
mock control, pQE-TriSystem was used to transfect cells. After incubation, 3 mL of fresh medium 
supplemented with 10% FBS was added to the transfected cells, which were then further incubated 
for 36 h. The success of transfection was verified by determining the fluorescence of control cells that 
had been transfected with pQE-TriSystem-GFP plasmid. Cellular proliferation was analyzed using 
flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA, USA), using mouse-anti-human Ki67-
FITC antibody (11-5699-41, eBioscience, San Diego, CA, USA). 
4.12. Statistical Analysis 
The GraphPadQuickCalcs unpaired t-test free web calculator was used for statistical analysis 
(http://graphpad.com/quickcalcs/ttest2) (accessed June 2019). 
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ASPRV1 Retroviral-like aspartic protease 1 
Ddi1 DNA damage-inducible protein 1 
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RF1/RF2PEG10 Gag-Pol-like protein encoded by PEG10 
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